ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.60
0.71%
US Tech 100
19,636.04
0.55%
S&P 500
5,770.20
0.55%
US Dollar vs CAD
1.43715
0.00%
Bitcoin
85,888.07
-0.31%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Arbutus Biopharma Corporation (ABUS) Share Price

Arbutus Biopharma Corporation

Arbutus Biopharma Corporation (ABUS)

NASDAQ
3.31
-0.06
(-1.78%)
Closed March 09 4:00PM
Delayed by 15 minutes
3.31
0.00
(0.00%)
After Hours: 6:39PM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
3.31
Bid
3.22
Ask
3.50
Volume
1,191,925
3.26 Day's Range 3.42
2.30 52 Week Range 4.725
Market Cap
627.217M
Previous Close
3.37
Open
3.42
Last Trade
5
@
3.38
Last Trade Time
Financial Volume
US$ 3,954,957
VWAP
3.3181
Average Volume (3m)
853,126
Shares Outstanding
189,491,685
Dividend Yield
-
PE Ratio
-8.61
Earnings Per Share (EPS)
-0.38
Revenue
18.14M
Net Profit
-72.85M

About Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid na... Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.tekmirapharm.com
Headquarters
Burnaby, British Columbia, Can
Founded
-
Arbutus Biopharma Corporation is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ABUS. The last closing price for Arbutus Biopharma was US$3.37. Over the last year, Arbutus Biopharma shares have traded in a share price range of US$ 2.30 to US$ 4.725.

Arbutus Biopharma currently has 189,491,685 shares outstanding. The market capitalization of Arbutus Biopharma is US$638.59 million. Arbutus Biopharma has a price to earnings ratio (PE ratio) of -8.61.

Ask ADVFN Intelligence (AI)

ABUS Latest News

More News

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
March 07 2025
ABUS (-1.78%)

Form 3 - Initial statement of beneficial ownership of securities
Edgar (US Regulatory)
March 06 2025
ABUS (-1.78%)

Form 3 - Initial statement of beneficial ownership of securities
Edgar (US Regulatory)
March 06 2025
ABUS (-1.78%)

Form 3 - Initial statement of beneficial ownership of securities
Edgar (US Regulatory)
March 06 2025
ABUS (-1.78%)

Form 3 - Initial statement of beneficial ownership of securities
Edgar (US Regulatory)
March 06 2025
ABUS (-1.78%)

Form 8-K - Current report
Edgar (US Regulatory)
March 03 2025
ABUS (-1.78%)

Form 8-K - Current report
Edgar (US Regulatory)
February 25 2025
ABUS (-1.78%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.08-2.35988200593.393.573.3110969393.41436137CS
4-0.07-2.071005917163.383.73.2359443683.403959CS
12-0.22-6.232294617563.533.73.118531263.34636942CS
26-1.27-27.72925764194.584.7253.119406993.69152167CS
520.5821.24542124542.734.7252.310268873.45266241CS
1560.4716.54929577462.844.7251.699405912.84850357CS
2600.4716.54929577462.8490.8821466263.72079891CS

ABUS - Frequently Asked Questions (FAQ)

What is the current Arbutus Biopharma share price?
The current share price of Arbutus Biopharma is US$ 3.31
How many Arbutus Biopharma shares are in issue?
Arbutus Biopharma has 189,491,685 shares in issue
What is the market cap of Arbutus Biopharma?
The market capitalisation of Arbutus Biopharma is USD 638.59M
What is the 1 year trading range for Arbutus Biopharma share price?
Arbutus Biopharma has traded in the range of US$ 2.30 to US$ 4.725 during the past year
What is the PE ratio of Arbutus Biopharma?
The price to earnings ratio of Arbutus Biopharma is -8.61
What is the cash to sales ratio of Arbutus Biopharma?
The cash to sales ratio of Arbutus Biopharma is 34.59
What is the reporting currency for Arbutus Biopharma?
Arbutus Biopharma reports financial results in USD
What is the latest annual turnover for Arbutus Biopharma?
The latest annual turnover of Arbutus Biopharma is USD 18.14M
What is the latest annual profit for Arbutus Biopharma?
The latest annual profit of Arbutus Biopharma is USD -72.85M
What is the registered address of Arbutus Biopharma?
The registered address for Arbutus Biopharma is 100, 8900 GLENLYON PARKWAY, GLENLYON BUSINESS PARK, BURNABY, BRITISH COLUMBIA, V5J 5J8
What is the Arbutus Biopharma website address?
The website address for Arbutus Biopharma is www.tekmirapharm.com
Which industry sector does Arbutus Biopharma operate in?
Arbutus Biopharma operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CAPSCapstone Holding Corp
US$ 3.50
(1,300.00%)
36.33k
ABLVAble View Global Inc
US$ 1.73
(137.18%)
5.13M
SUNESUNation Energy Inc
US$ 0.402999
(127.55%)
476.73M
BTOGBit Origin Ltd
US$ 0.6117
(118.46%)
618.03M
DWTXDogwood Therapeutics Inc
US$ 6.63
(49.66%)
25.77M
ALBTAvalon GloboCare Corporation
US$ 6.96
(-36.15%)
577.55k
SCNXScienture Holdings Inc
US$ 1.55
(-35.68%)
1.59M
ACXPAcurx Pharmaceuticals Inc
US$ 0.4572
(-29.88%)
1.18M
RETOReTo Eco Solutions Inc
US$ 5.42
(-27.73%)
108.27k
OCTOEightco Holdings Inc
US$ 1.08
(-27.03%)
336.99k
BTOGBit Origin Ltd
US$ 0.6117
(118.46%)
622.67M
SUNESUNation Energy Inc
US$ 0.402999
(127.55%)
482.05M
NVDANVIDIA Corporation
US$ 112.69
(1.92%)
341.94M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 10.675
(-0.70%)
143.04M
ICONIcon Energy Corporation
US$ 0.169898
(17.17%)
142.23M

ABUS Discussion

View Posts
db7 db7 6 days ago
https://www.globenewswire.com/news-release/2025/03/03/3035733/14025/en/Genevant-Sciences-and-Arbutus-Biopharma-Initiate-International-Patent-Infringement-Enforcement-Actions-Against-Moderna.html
👍️0
db7 db7 1 week ago
some scenarios(imo?):

BEST case scenario: A letter of intent to completely divest of the HBV assets 'prior' to Pfizer Markman ruling for a respectectable amount; this would put a solid floor at the purchase price and leave risk-free upside into Pfizer Markman result. HUGE cherry on top if result leaned heavily our way. This 'could be' a scenario where we see $15+ ??

WORST case scenario: Pfizer Markman comes out prior to HBV deal and leans towards Pfizer. Maybe temporarily drops share price to $2.50 to $2.75(?) Then we seem to be weak and lose some of our HBV bargaining power(?)


Timing?

HBV:
Based on commentary when the new directors were announced, 'possibly' hear about an HBV transaction prior to the annual general meeting in mid-March(?)
.. BUT obviously could drag out.... 'should be' this year????

Pfizer Markman ruling:
Supposedly 1st half 2025 but in looking at the Judge's past Markman rulings it could be ~8 months'ish???

Moderna Summary Judgement in regards to Gov't contracts..etc:
Q2/Q3 if i recall correctly

Moderna Hearing:
Sept 2025

Qilu payment:
1st half 2025



Would LOVE to have a bunch of solid wins in 1st half 2025....
👍️0
db7 db7 1 week ago
tell me about it!?! ... and of course i keep rolling calls on her............. someday?!? 'i think' this will at minimum double this year with max downside to around $2.50ish 'if' they completely lost on pfizer markman(?)
👍️0
MWM MWM 1 week ago
long wait on this one. Maybe some day!
👍️ 1
db7 db7 2 weeks ago
"The Company will temporarily pause participation in investor meetings and conferences while the new board and management team reviews development plans and strategic options for its hepatitis B programs."
👍️0
db7 db7 2 weeks ago
https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-announces-changes-board-directors-and-appointment
👍️0
db7 db7 2 weeks ago
Whitefort message and adding: https://www.sec.gov/Archives/edgar/data/1447028/000092189525000560/xslSCHEDULE_13D_X01/primary_doc.xml
👍️0
db7 db7 3 weeks ago
ROIV filed sc-13d yesterday: "Roivant and its representatives are evaluating potential near-term changes to the composition of the board of directors and management of the Issuer. Roivant's representatives may also be engaged in discussions related to such potential changes in the board of directors and management of the Issuer with other shareholders of the Issuer. "
👍️0
Monksdream Monksdream 3 weeks ago
ABUS under $4

👍️0
MWM MWM 2 months ago
ABUS made it on mad money tonight, the ultimate spec! 

https://www.cnbc.com/2025/01/13/cramers-lightning-round-arbutus-biopharma-is-the-ultimate-spec.html
👍️ 1
MWM MWM 2 months ago
I'll look now 👍🏽
👍️0
db7 db7 2 months ago
MWM see today’s update. Qilu milestones coming and no more atm

Pfizer Markman results ‘soon’. Assuming they are positive we should have liftoff. ATM program killed the Moderna Markman last year and won’t be used during Pfizer results it sounds like

Now to just get a decisive victory!?!???
👍️0
db7 db7 4 months ago
nice new Blackrock 13F: https://stocktwits.com/bs010101/message/592459944
👍️0
db7 db7 4 months ago
2 days to AASLD...
👍️0
mick mick 5 months ago
👍️0
db7 db7 5 months ago
2 late breakers for AASLD: https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-announces-multiple-abstracts-highlighting-imdusiran-data
👍️0
mick mick 6 months ago
https://www.stockscores.com/charts/charts/?ticker=ABUS
👍️0
mick mick 6 months ago
ABUS
Arbutus Biopharma Corporation
4.5488
0.0388 (0.86%)
Volume: 1,579,948
Day Range: 4.39 - 4.56
Last Trade Time: 7:46:00 PM EDT
👍️0
db7 db7 6 months ago
breaking out; dare i say 'someone' knows 'something'(?)
👍️0
db7 db7 6 months ago
ARBUTUS PHARMA CORP. et al v. PFIZER INC. et al "Please take notice that an in-person Markman Hearing is hereby scheduled for 12/18/2024 at 10:30AM in Trenton- Courtroom 4W. So Ordered by Judge Zahid N. Quraishi on 9/3/2024. (kas)"
👍️0
db7 db7 6 months ago
ABUS over $4
👍️0
Monksdream Monksdream 6 months ago
ABUS under $4
👍️0
DewDiligence DewDiligence 7 months ago
ABUS pares pipeline–reduces workforce 40%:

https://finance.yahoo.com/news/arbutus-reports-second-quarter-2024-113000099.html

The company’s will focus on clinical development of Imdusiran regimens for HBV, but will terminate research on new HBV compounds.

Oddly (for the reason mentioned at the bottom of #msg-174556022), ABUS opted to retain its oral PD-1 program.
👍️0
Rockurstocks Rockurstocks 8 months ago
Not for long! $ABUS$
👍️0
Monksdream Monksdream 8 months ago
ABUS under $4
👍️0
mick mick 8 months ago
ABUS
Arbutus Biopharma Corporation
3.645
-0.135 (-3.57%)
Volume: 449,700
Day Range: 3.645 - 3.845
Last Trade Time: 2:29:04 PM EDT
👍️0
Monksdream Monksdream 8 months ago
ABUS new 52/week high
👍️0
db7 db7 8 months ago
👍️0
db7 db7 9 months ago
https://www.sec.gov/Archives/edgar/data/1447028/000089542124000390/ArbutusABUS.txt
👍️0
db7 db7 9 months ago
New Presentation: https://investor.arbutusbio.com/static-files/f33bde13-92b8-48c4-a40e-36cf6dd25852
👍️0
db7 db7 9 months ago
Poster for EASL https://www.arbutusbio.com/wp-content/uploads/2024/06/WED-371-Yuen-et-al-AB-729-201-IFN-poster-EASL-2024_FINAL.pdf
👍️0
mick mick 9 months ago
ABUS
Arbutus Biopharma Corporation
3.341
-0.019 (-0.57%)
Volume: 534,638
Day Range: 3.30 - 3.385
Last Trade Time: 12:14:00 PM EDT
Delayed by 15 minutes
👍️0
db7 db7 10 months ago
EASL June 6-8th:
https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-present-imdusiran-data-easl-congress-2024

"
HBsAg = LLOQ (lower limit of quantification) with detectable anti-HBs was observed at end-of-treatment in 28% of subjects who received 4 or 6 doses of imdusiran plus 24 weeks of IFN
"
👍️0
db7 db7 10 months ago
Arbutus is waking up a little following yesterday's Motion to Dismiss with Acuitas:
https://www.law360.com/ip/articles/1839088/judge-tosses-acuitas-covid-biotech-ip-suit-

other important events of late include:

1) company stating they have stopped their ATM and don't see a need to use it the rest of this year

2) the Markman order against Moderna that went in their favor:
https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-biopharma-announces-claim-construction-ruling-its

3) Activist becoming involved:
https://www.morningstar.com/news/business-wire/20240517970994/whitefort-capital-publishes-open-letter-to-arbutus-biopharma-shareholders-outlining-paths-to-maximize-value
👍️0
db7 db7 10 months ago
issue here, now, might be too many open $3 calls? will mm's hold her under....
👍️0
db7 db7 10 months ago
mgmt killed this stock with that ATM; imo, used in a suspicious manner... ie: they put a lid on her on the markman order release at $3ish .. WHY would you do that? They could have raised same money at double the price
👍️0
MWM MWM 10 months ago
Nice!
👍️0
db7 db7 10 months ago
https://www.businesswire.com/news/home/20240517970994/en/
👍️0
db7 db7 10 months ago
from Whitefort's 13D filed today: "The Reporting Persons have conveyed their view to the Issuer’s Board of Directors (the “Board”) that the current market price of the Shares does not reflect the Issuer’s intrinsic value. The Reporting Persons have requested that the Board immediately terminate the Issuer’s ATM program and explore all strategic options for the Issuer’s hepatitis B virus (HBV) portfolio. The Reporting Persons hope to continue to work constructively and collaboratively with the Board on these critical initiatives and intend to actively engage with shareholders and others regarding their views."
👍️0
Monksdream Monksdream 10 months ago
ABUS under $3
👍️0
mick mick 11 months ago
TWTR
Twitter Inc
53.70
0.00 (0.00%)
Volume:
👍️0
Monksdream Monksdream 11 months ago
ABUS new 52 hi
👍️0
db7 db7 11 months ago
looking a little better today; i guess it's going to be slow and steady and not the rocket on markman day like i hoped. i think this is looking really good med-long term on the litigation from after that markman ruling

also, looking forward to EASL in june
👍️0
mick mick 11 months ago
ABUS
Arbutus Biopharma Corporation
3.00
0.08 (2.74%)
Volume: 1,253,240
Day Range: 2.86 - 3.11
Bid: 2.99
Ask: 3.00
Last Trade Time: 9:56:51 AM EDT
Total Trades: 3,890
👍️0
mick mick 11 months ago
ABUS
Arbutus Biopharma Corporation
3.00
0.08 (2.74%)
Volume: 1,253,240
Day Range: 2.86 - 3.11
Bid: 2.99
Ask: 3.00
Last Trade Time: 9:56:51 AM EDT
Total Trades: 3,890
👍️0
mick mick 11 months ago
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM
👍️0
mick mick 11 months ago
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM
👍️0
mick mick 11 months ago
Arbutus to Participate in Two Upcoming Investor Conferences
03/08/2024 07:30:00 AM
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM
👍️0
mick mick 11 months ago
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
04/04/2024 08:30:49 AM
Arbutus to Participate in Two Upcoming Investor Conferences
03/08/2024 07:30:00 AM
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM
👍️0
Paullee Paullee 11 months ago
07:15 AM EDT, 04/04/2024 (MT Newswires) -- A US court ruled against Moderna (MRNA) in a patent infringement case by Arbutus (ABUS) over its COVID-19 vaccines, Reuters reported Wednesday.

US District Judge Mitchell Goldberg interpreted the patents in ways that favored Arbutus' case and hurt Moderna', Reuters reported.

Arbutus sued Moderna in 2022, claiming the company's COVID-19 vaccine impinged on its patents for lipid nanoparticles that shield the vaccine's mRNA from the body's immune system.

Moderna and Arbutus did not immediately respond to MT Newswires' requests for comment.
👍️0

Your Recent History

NASDAQ
ABUS
Arbutus Biopharma
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads